Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical Inks Distribution Deal with Fisher HealthCare

NEW YORK (GenomeWeb News) – Response Biomedical today said that it has signed a new, nonexclusive deal for Fisher HealthCare to distribute its portfolio of infectious disease tests in the US.

Fisher HealthCare, which is part of Thermo Fisher Scientific, will distribute Response Bio's Infectious Disease Point of Care test panel, which includes the Ramp Flu A + B test and the Ramp RSV test. The assays run on the firm's Ramp 200 system.

"This is a key strategic agreement for Response as we continue our investment into the US marketplace for POC testing," Tim Shannon, SVP of worldwide sales and marketing for Response Biomedical, said in a statement. "The knowledge and experience of Fisher HealthCare in this market is a vital part of our strategy to substantially increase our penetration into this highly competitive region."

Earlier this month, Vancouver, British Columbia-based Response Bio signed a US distribution deal with Labsco covering its cardiovascular portfolio of Ramp products.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.